FindMyKOL
Clinical trialNCT04512716RecruitingEarly phase 1Interventional

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

SponsorMemorial Sloan Kettering Cancer CenterEnrollment12B ALLB-ALLDLBCLDLBCL Activated B-Cell TypeDLBCL Germinal Center B-Cell TypeDLBCL Unclassifiable+5 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Memorial Sloan Kettering at Basking Ridge (limited Protocol Activities)

    Basking Ridge, New Jersey, United States

    Recruiting
  • Memorial Sloan Kettering Monmouth (limited Protocol Activities)

    Middletown, New Jersey, United States

    Recruiting
  • Memorial Sloan Kettering Bergen (limited Protocol Activities)

    Montvale, New Jersey, United States

    Recruiting
  • Memorial Sloan Kettering Suffolk - Commack (limited Protocol Activities)

    Commack, New York, United States

    Recruiting
  • Memorial Sloan Kettering Westchester (limited Protocol Activities)

    Harrison, New York, United States

    Recruiting
  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

    Recruiting
  • Memorial Sloan Kettering Nassau (limited Protocol Activites)

    Rockville Centre, New York, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

131-I ApamistamabChimeric antigen receptor T-cells
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
2 Feb 2021
Primary completion
31 Jan 2027
Completion
31 Jan 2027
Last update posted
17 Feb 2026
Registered enrollment
12
Registry id
NCT04512716

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.